Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover

Publication Type:
Poster


Citation:

Morgan GJ, San Miguel J, Dhanasiri S, Lee D, Palumbo A, Facon T, Zaki MH, Yu X, Sternas LA, Jacques C, Weisel KC, Offner F and Dimopoulos MA. Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, United States of America. 30 May – 3 June 2014. Poster 8593.

 


Link to publication ⟶

⟵ Back to Search Results